Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.48 |
| ▸ | ITGAV | P06756 | 18/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.44 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211407 | 0.96 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB5TP53 | |
| Acetic Acid SCHEMBL7216501 | 0.82 | KMT2A (0.42) | ITGB3ITGA2BALDH1A1 | |
| SCHEMBL7217848 | 0.82 | ITGB3 (0.48) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7216435 | 0.79 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL7211416 | 0.78 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7217842 | 0.74 | ITGB3 (0.45) | ITGB3ITGAVITGA2BITGB5TP53 | |
| SCHEMBL7217807 | 0.74 | ITGA4 (0.42) | ITGB3ITGAVSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7211410 | 0.71 | ITGB3 (0.48) | ITGB3ITGAVITGA2BITGB5TP53 | |
| SCHEMBL7216458 | 0.70 | ITGB3 (0.51) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7216519 | 0.69 | ITGB3 (0.55) | ITGB3ITGAVITGA2BITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620820-B2 | Imidazole dione or one, thione derivatives as antitumor and antiinflammatory agents, also treats cardiovascular disease, nephropathies and retinopathies | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-09-16 | — | — | US | disclosed |
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | HOECHST AKTIENGESELLSCHAFT | 2002-08-29 | — | — | US | disclosed |
| EP-0796855-B1 | Inhibitors of bone resorption and vitronectin receptor antagonists | HOECHST AG (DE) | 2002-02-06 | — | — | EP | disclosed |
| US-6218415-B1 | THERAPY OF BONE REABSORPTION BY OSTEOCLASTS, TUMOR GROWTH AND TUMOR METASTASIS, INFLAMMATION, CARDIOVASCULAR DISEASE, NEPHROPATHIES AND RETINOPATHIES | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-04-17 | — | — | US | disclosed |
| EP-0796855-A1 | Inhibitors of bone resorption and vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | ADGRF1, CALCR, SOST | ITGB3 500/4885ITGAV 478/4885ITGA2B 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.